Proton beam therapy significantly lowers risk of side effects, reveals major study

Professor Karol Sikora, chief medical officer of Proton Partners International which operates the Rutherford Cancer Centres, the largest network of proton beam therapy facilities in the UK and the world’s leading developer of proton therapy services, said: “This is a very significant study that adds to the growing body of evidence on the benefits of proton beam therapy. There has been a tremendous breakthrough in the UK over the past year in the provision of PBT facilities.

“At our own centres we have seen first-hand patients coming in for treatment with very little disruption to their daily lives. The most striking aspect about the treatment of these patients is how well they feel during and after treatment and the reduction in side effects gives them confidence that their cancer can be treated successfully. The more research data we have on PBT the better and this study is a milestone moment. Although PBT is not a panacea for all cancers, it can be very effective while being less toxic and this is proving an attractive form of treatment for patients.”